Dosing & Uses
Dosage Forms & Strengths
acrivastine/pseudoephedrine
capsule
- 8mg/60mg
Seasonal Allergic Rhinitis or Nasal Congestion
8 mg/60 mg (1 capsule) PO q4-6h
>14 days continuous treatment efficacy not adequately investigated
Renal Impairment
CrCl>48mL/min: Dose adjustment not necessary
CrCl <48mL/min: Not recommended
Hepatic Impairment
Not studied
Dosage Forms & Strengths
acrivastine/pseudoephedrine
capsule
- 8mg/60mg
Seasonal Allergic Rhinitis or Nasal Congestion
<12 years: Safety and efficacy not established
>12 years: 8 mg/60 mg (1 capsule) PO q4-6h
>14 days continuous treatment efficacy not adequately investigated
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
1-10%
Somnolence
Nervousness
Insomnia
Dry mouth
<1%
Headache
Dizziness
Asthenia
Nausea
Dyspepsia
Pharyngitis
Cough increase
Dysmenorrhea
Postmarketing Reports
Rare serious hypersensitivity reactions manifested by anaphylaxis, angioedema, bronchospasm, and erythema multiforme
Pseudoephedrine
- Tachycardia
- Palpitations
- Serious skin reactions (acute generalized exanthematous pustulosis)
Warnings
Contraindications
Hypersensitivity to acrivastine or other alkylamine antihistamines
Hypersensitivity to pseudoephedrine or other sympathomimetic amines
Severe hypertension
Severe coronary artery disease
Patients taking monoamine oxidase (MAO) inhibitors and for 14 days after stopping use of an MAO inhibitor
Cautions
Due to potential for sedation, assess individual responses before engaging in any activity requiring mental alertness, such as driving a motor vehicle or operating machinery
Concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of CNS performance and should be avoided
Not adequately studied for relieving common cold symptoms
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Unknown whether acrivastine is distributed in breast milk, caution advised ; pseudoephedrine is excreted in human milk, caution advised
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Acrivastine exhibits H1-antihistaminic receptor activity, which prevents histamine from binding to its receptor in target cells
Pseudoephedrine: Indirect sympathomimetic agent, releases norepinephrine from adrenergic nerves
Half-Life
Acrivastine 1.9-3.5 hr; propionic acid metabolite 3.8 hrs
Pseudoephedrine 5-8 hr
Absorption
Rapid and complete
Vd
Acrivastine 0.46 L/kg
Pseudoephedrine 3 L/kg
Peak Plasma Time
Acrivastine 1.1 hr
Pseudoephedrine 1.97 hr
Peak Plasma Concentration
Acrivastine 227 ng/ml
Pseudoephedrine 422 ng/ml
Protein Bound
Acrivastine 50%
Pseudoephedrine minimal
Metabolism
Acrivastine 11% to propionic acid metabolite
Clearance
Acrivastine 2.9 mL/min/kg
Pseudoephedrine 5.9 mL/min/kg
Excretion
Acrivastine: feces (13%) urine (84%)
Pseudoephedrine: 55-75% renal (dependent on urine pH)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
